ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

THE VIABILITY OF PETHIDINE AND TRAMADOL IN THE TREATMENT OF POSTOPERATIVE SHIVERING IN PATIENTS

AUTHORS:

Dr. Muhammad Idrees Khan, Dr. Said Amin, Dr. Asif Nawaz

ABSTRACT:

Objective: Post-operative chills are a normal problem and occur in many cases recovering from universal or provincial anesthesia, postponing recovery and release from the medical clinic. The current purpose was to analyze viability of pethidine and tramadol in cure of postoperative shivering in cases experiencing elective medical intervention underneath GA. Methods: This dual-blind, randomized, measured, preliminary study of visually impaired patients was led from October 2017 to April 2018 at Sir Ganga Ram Hospital, Lahore. Due to the non-probabilistic back-to-back inspection technique, an example of 50 cases in every set was used. Cases by fever, a past of spasms, any neuromuscular irregularities, and those who received vasoconstrictors, adrenergic agonists, pethidine, tramadol, cold fluids, or a large blood transfusion during the medical procedure remained omitted. Patients with postoperative tremor were randomly assigned to 2 sets using a lottery technique. Patients in Group T received tramadol 2.0 mg/kg intravenously and patients in Group P received pethidine 0.6 mg/kg in a 15 mL syringe gradually over 5 minutes. Altogether cases were tested afterward 17 minutes of initiation of intravenous medication to decide on the viability of medicine. Results: Tramadol seemed to remain viable in 92% of cases by postoperative chills while pethidine was potent in 78.6% of cases (p > 0.06). Conclusion: Pethidine 0.6 mg/kg and tramadol 2.0 mg/kg administered intravenously gradually over 6 minutes were both viable in controlling post-anesthetic chills after GA in the common cases. Key words: GA; Pethidine; Postoperative shivering; Tramadol.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.